Overview Study to Assess the Efficacy of XPro™ in Patients With Mild Alzheimer's Disease With Biomarkers of Inflammation Status: Recruiting Trial end date: 2023-06-19 Target enrollment: Participant gender: Summary The purpose of this study is to measure cognitive and biological biomarkers in subcutaneously administered XPro™ or placebo in patients with mild ADi. Phase: Phase 2 Details Lead Sponsor: Inmune Bio, Inc.